Histochemistry and Cell Biology

, Volume 120, Issue 6, pp 493–503 | Cite as

Heparanase mRNA expression during fracture repair in mice

  • Masamichi Saijo
  • Riko Kitazawa
  • Motowo Nakajima
  • Masahiro Kurosaka
  • Sakan Maeda
  • Sohei Kitazawa
Original Paper

Abstract

Bone fracture healing takes place through endochondral ossification where cartilaginous callus is replaced by bony callus. Vascular endothelial growth factor (VEGF) is a requisite for endochondral ossification, where blood vessel invasion of cartilaginous callus is crucial. Heparanase is an endoglucuronidase that degrades heparan sulfate proteoglycans (HSPG) and releases heparin-binding growth factors including VEGF as an active form. To investigate the role of heparanase in VEGF recruitment during fracture healing, the expression of heparanase mRNA and VEGF, and vessel formation were examined in mouse fractured bone. On days 5 and 7 after the fracture, when mesenchymal cells proliferated and differentiated into chondrocytes, heparanase mRNA was detected in osteo(chondro)clasts and their precursors, but not in the inflammatory phase (day 3). On day 10, both VEGF and HSPG were produced by hypertrophic chondrocytes of the cartilaginous callus and by osteoblasts of the bony callus; numerous osteo(chondro)clasts resorbing the cartilage expressed strong heparanase signals. Adjacent to the cartilage resorption sites, angiogenesis with CD31-positive endothelial cells and osteogenesis with osteonectin-positive osteoblasts were observed. On days 14 and 21, osteoclasts in the woven bone tissue expressed heparanase mRNA. These data suggest that by producing heparanase osteo(chondro)clasts contribute to the recruitment of the active form of VEGF. Thus osteo(chondro)clasts may promote local angiogenesis as well as callus resorption in endochondral ossification during fracture healing.

Keywords

Heparanase Fracture healing Osteoclast VEGF 

References

  1. Bar-Ner M, Mayer M, Schirrmacher V, Vlodavsky I (1986) Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix. J Cell Physiol 128:299–306PubMedGoogle Scholar
  2. Bourque WT, Gross M, Hall BK (1993) Expression of four growth factors during fracture repair. Int J Dev Biol 37:573–579PubMedGoogle Scholar
  3. Brown CC, Hembry RM, Reynolds JJ (1989) Immunolocalization of metalloproteinases and their inhibitor in the rabbit growth plate. J Bone Joint Surg Am 71:580–593PubMedGoogle Scholar
  4. Buckwalter AJ, Einhorn AT, Bolander EM, Cruess LR (1996) Healing of the musculoskeletal tissues. In: Rockwood AC Jr, Green PD, Bucholz WR, Heckman DJ (eds) Rockwood and Green’s fracture in adults, 4th edn, vol 1. Lippincott-Raven, Philadelphia, pp 261–304Google Scholar
  5. Cheng SY, Nagane M, Huang HJ, Cavenee WK (1997) Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF(121) and VEGF(165) but not VEGF(189). Proc Natl Acad Sci U S A 94:12081–12087CrossRefPubMedGoogle Scholar
  6. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi B, Neufeld G (1995) VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270:11322–11326CrossRefPubMedGoogle Scholar
  7. Couffinhal T, Silver M, Zheng L, Kearney M, Witzenbichler B, Isner MJ (1998) Mouse model of angiogenesis. Am J Pathol 152:1667–1679PubMedGoogle Scholar
  8. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I (1992) Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest 90:2013–2021PubMedGoogle Scholar
  9. Fujii H, Kitazawa R, Maeda S, Mizuno K, Kitazawa S (1999) Expression of platelet-derived growth factor proteins and their receptor α and β mRNAs during fracture healing in the normal mouse. Histochem Cell Biol 112:131–138CrossRefPubMedGoogle Scholar
  10. Gerber PH, Vu HT, Ryan MA, Kowalski J, Werb Z, Ferrara N (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623–628PubMedGoogle Scholar
  11. Glowacki J (1998) Angiogenesis in fracture repair. Clin Orthop 355:82–89Google Scholar
  12. Goad DL, Rubin J, Wang H, Tashjian AH Jr, Patterson C (1996) Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137:2262–2268PubMedGoogle Scholar
  13. Gordon MY, Riley GP, Watt SM, Greaves MF (1987) Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature 326:403–405PubMedGoogle Scholar
  14. Harada S, Rodan SB, Rodan GA (1995) Expression and regulation of vascular endothelial growth factor in osteoblasts. Clin Orthop 313:76–80PubMedGoogle Scholar
  15. Harper J, Kalgsbrun M (1999) Cartilage to bone: angiogenesis leads the way. Nat Med 5:617–618CrossRefPubMedGoogle Scholar
  16. Hiltunen A, Vuorio E, Aro HT (1993) A standardized experimental fracture in the mouse tibia. J Orthop Res 11:305–312PubMedGoogle Scholar
  17. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H (1999) MT1-MMP-deficent mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99:81–92PubMedGoogle Scholar
  18. Houck KA, Ferrara N, Winer J, Cachianes G, Li B Leung DW (1991) The vascular endothelial growth factor family: identification of fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806–1814PubMedGoogle Scholar
  19. Ishai-Michaeli R, Eldor A, Vlodavsky I (1990) Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Reg 1:833–842Google Scholar
  20. Joyce ME, Jingushi S, Scully SP, Bolander ME (1991) Role of growth factors in fracture healing. Prog Clin Biol Res 365:391–416PubMedGoogle Scholar
  21. Kashimoto H, Kitazawa R, Maeda S, Mizuno K, Kitazawa S (1998) Modulation of osteonectin and osteopontin expression during fracture healing of mouse bone tissue. Acta Histochem Cytochem 31:501–508Google Scholar
  22. Kiefer MC, Stephans JC, Crawford K, Okino K, Barr PJ (1990) Ligand-affinity cloning and structure of a cell surface heparan sulfate proteoglycan that binds basic fibroblast growth factor. Proc Natl Acad Sci U S A 87:6985–6989PubMedGoogle Scholar
  23. Kitazawa S, Ross FP, McHugh K, Teitelbaum SL (1995) Interleukin-4 induces expression of the integrin alpha v beta 3 via transactivation of the beta 3 gene. J Biol Chem 270:4115–4120PubMedGoogle Scholar
  24. Kitazawa S, Kitazawa R, Maeda S (1999) In situ hybridization with polymerase chain reaction-derived single-stranded DNA probe and S1 nuclease. Histochem Cell Biol 111:7–12PubMedGoogle Scholar
  25. Lacey DL, Timms E, Tan TL, Kelly MJ, Dunstan CU, Burgess T, Elliot R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedGoogle Scholar
  26. Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z, Vlodavsky I (1985) Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. J Clin Invest 76:1306–1313PubMedGoogle Scholar
  27. Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL (1983) Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 220:611–612PubMedGoogle Scholar
  28. Nakajima M, Irimura T, Ferrante DN, Nicolson LG (1984) Metastatic melanoma cell heparanase. J Biol Chem 259:2283–2290PubMedGoogle Scholar
  29. Nakajima M, Irimura T, Nicolson LG (1988) Heparanase and tumor metastasis. J Cell Biochem 36:157–167PubMedGoogle Scholar
  30. Niida S, Kaku M, Amano H (1999) Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190:293–298CrossRefPubMedGoogle Scholar
  31. Park JE, Keller GA, Ferrara N (1993) Vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317–1326PubMedGoogle Scholar
  32. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G (1997) VEGF145: a secreted VEGF form that binds to extracellular matrix. J Biol Chem 272:7151–7158PubMedGoogle Scholar
  33. Poole AR (1991) The growth plate: cellular physiology, cartilage assembly and mineralization. In: Hall BK, Newman SA, Boca R (eds) Cartilage: molecular aspects. CRC Press, Boca Raton, pp 179–211Google Scholar
  34. Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomfield F, Dexter TM (1988) Heparan sulfate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 332:376–378PubMedGoogle Scholar
  35. Suda T, Takahashi N, Udagawa N (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357PubMedGoogle Scholar
  36. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher (1983) Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 43:2704–2711PubMedGoogle Scholar
  37. Vlodavsky I, Ishai-Michaeli R, Bar-Ner M, Fridman R, Horowitz TA, Fuks Z, Biran S (1988) Involvement of heparanase in tumor metastasis and angiogenesis. Isr J Med Sci 24:464–470PubMedGoogle Scholar
  38. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z (1991) Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 16:268–271CrossRefPubMedGoogle Scholar
  39. Vu TH, Shipley JM, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411–422PubMedGoogle Scholar
  40. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Masamichi Saijo
    • 1
  • Riko Kitazawa
    • 1
  • Motowo Nakajima
    • 2
  • Masahiro Kurosaka
    • 3
  • Sakan Maeda
    • 1
  • Sohei Kitazawa
    • 1
  1. 1.Division of Molecular PathologyKobe University Graduate School of MedicineKobeJapan
  2. 2.Discovery Research, Tsukuba Research InstituteNovartis Pharma K. K.IbarakiJapan
  3. 3.Division of Orthopaedic SurgeryKobe University Graduate School of MedicineKobeJapan

Personalised recommendations